Dr. Robert Orlowski: Progress in the Treatment of Multiple Myeloma

In this episode of The Onco'Zine Brief, Sonia Portillo and Peter Hofland ask Robert Z. Orlowski, MD, PhD, chairman, Ad Interim, Director of Myeloma and professor of Medicine in the Departments of Lymphoma, Myeloma and Experimental Therapeutics in the Division of Cancer Medicine at MD Anderson in Houston, Texas, about his thoughts and unique perspective on research and the recent advancements in the treatment multiple myeloma, including promising results with a drug called carfilzomib (marketed as Kyprolis® by Amgen), which has become the first treatment proven to extend the overall survival of patients with relapsed multiple myeloma when compared to the current standard of care.